I learned from the recent AVEO, Tivo FDA debacle, there are several approved drugs for RCC that work OK, but only for a limited time and with harsh side effects. There's room for improvement in efficacy and safety with blockbuster potential in this indication. The ONXX drug sells over $1BB and is not all that efficacous, so there's room for improvement and large profits.
I doubt anything works for Glioma, so the hurdle should be low, maybe AMGN can get on a very fast track/breakthrough.
AMG 595 - This TAP compound, in development by Amgen, is in Phase I clinical testing for recurrent malignant glioma.
AMG 172 - This TAP compound, in development by Amgen, is in Phase I clinical testing for clear cell renal cell carcinoma (ccRCC).